24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

1530 Poster Discussion Session (Board #19), Sun, 8:00 AM-12:00 PM and<br />

11:30 AM-12:30 PM<br />

Potential risk <strong>of</strong> asbestos exposure among Japanese general population:<br />

Japanese general screening study for asbestos-related diseases (JGSARD).<br />

Presenting Author: Nobuhiko Seki, Teikyo University School <strong>of</strong> Medicine,<br />

Tokyo, Japan<br />

Background: The number <strong>of</strong> patients with pleural mesothelioma and lung<br />

cancer associated with asbestos exposure has recently been increasing in<br />

Japan. The aim <strong>of</strong> this study was to evaluate the results <strong>of</strong> screening for<br />

asbestos-related diseases in a group <strong>of</strong> Japanese general population.<br />

Methods: This prospective study was approved by the institutional review<br />

board. From 2006 to 2008, 9810 subjects (5283 men and 4527 women;<br />

mean age, 57 years) underwent chest radiography and low-dose CT<br />

examinations in 26 institutions in Japan. Among them, 6286 (64.1%)<br />

subjects underwent subsequent CT examinations after 2 years <strong>of</strong> interval.<br />

<strong>Clinical</strong> information such as histories <strong>of</strong> smoking and asbestos exposure<br />

was reviewed. Images were interpreted independently by 15 experienced<br />

pulmonologists or chest radiologists. Results: The history <strong>of</strong> asbestos<br />

exposure was definitely present in 1253 (12.8%) subjects, possibly<br />

present in 2058 (21.0%), and absent in 6499 (66.2%). On chest<br />

radiograph, pleural plaque and thickening were seen in 61 (0.6%) and 65<br />

(0.6%) subjects, respectively. On low-dose CT, pleural plaque and thickening<br />

were identified in 264 (2.7%) and 245 (2.5%) subjects, respectively,<br />

and non-calcified pulmonary nodule/mass was seen in 1003 (10.2%).<br />

Furthermore, lung cancer was identified in 29 (0.3%) subjects. The history<br />

<strong>of</strong> asbestos exposure was not confirmed in 77 out <strong>of</strong> 264 subjects (29.2%)<br />

having pleural plaques on low-dose CT. Based on the logistic regression<br />

analysis, pleural plaque on low-dose CT was significantly correlated with<br />

male, age more than 60 years, smoking, and a history <strong>of</strong> asbestos exposure.<br />

Especially, total residential period in asbestos factory area as well as<br />

asbestos exposure work period showed significantly increased relative risk<br />

every 10 years. Similarly, lung cancer was significantly correlated with age<br />

more than 60 years, a history <strong>of</strong> asbestos exposure, and presence <strong>of</strong> pleural<br />

plaques. Conclusions: Our results indicate the presence <strong>of</strong> pleural plaques<br />

on low-dose CT among Japanese general population is closely associated<br />

with potential risk <strong>of</strong> asbestos exposure. However, about 30% <strong>of</strong> such<br />

subjects are not aware <strong>of</strong> a history <strong>of</strong> asbestos exposure.<br />

1533 Poster Discussion Session (Board #22), Sun, 8:00 AM-12:00 PM and<br />

11:30 AM-12:30 PM<br />

<strong>Clinical</strong> characteristics and natural history <strong>of</strong> patients with squamous cell<br />

lung carcinoma with FGFR1 amplification. Presenting Author: Marc Bos,<br />

Lung Cancer Group Cologne, Department I <strong>of</strong> Internal Medicine and Center<br />

for Integrated Oncology, University Hospital Cologne, Cologne, Germany<br />

Background: FGFR1 amplifications have been described as a promising<br />

oncogenic target in squamous cell lung cancer. Here we aimed at<br />

describing the clinical characteristics and natural history <strong>of</strong> FGFR1amplified<br />

squamous cell lung cancer patients. Methods: From 01/2011 to 01/2012<br />

we screened 553 squamous cell lung cancer patients in our Network for<br />

Molecular Screening <strong>of</strong> Lung Cancer for the presence <strong>of</strong> FGFR1 amplifications<br />

by FISH analysis in accordance with the local ethics committee.<br />

FGFR1 was defined as amplified if the ratio <strong>of</strong> FGFR1 copies to centromeric<br />

copies was above 2 or if more than 50% <strong>of</strong> tumor cells showed 5 copies or if<br />

more than 15% <strong>of</strong> tumor cells demonstrated clusters <strong>of</strong> FGFR1. <strong>Clinical</strong><br />

data were collected by extracting information from medical records, the<br />

local cancer registry and by questioning treating physicians and patients.<br />

Results: FGFR1FISH analysis could be performed in 95% <strong>of</strong> the cases and<br />

was amplified in 16%. Of the amplified cases 75 % were male and 25%<br />

female without significant enrichment for male or female. The median age<br />

<strong>of</strong> the patients at diagnosis was 67 yrs (range 46 - 82). Stage at<br />

presentation was: 16% I; 17.3% II; 26.7% IIIa, 40% IIIb/IV. 97,3% <strong>of</strong> the<br />

patients were former or active smokers with a median <strong>of</strong> 40 pack years. The<br />

median progression free survival <strong>of</strong> patients with stage IIIb/IV disease was<br />

11 months (95% CI 8-14; n�14). The median overall survival was not yet<br />

reached after a median follow-up time <strong>of</strong> 14 months (95% CI 11 - 17;<br />

n�24). We further screened for co-existing genetic lesions such as<br />

mutations in EGFR, BRAF, KRAS, PIK3CA as well as translocations <strong>of</strong> ALK<br />

and amplifications <strong>of</strong> ERBB2. Two patients demonstrated co-occurring<br />

PIK3CA mutations and one a BRAFmutation. Conclusions: Screening for<br />

FGFR1 is feasible under routine clinical conditions. By implementation <strong>of</strong> a<br />

regional molecular screening network the ability to screen for FGFR1<br />

amplification was successfully expanded to non-academic centers and<br />

private practices. FGFR1 amplifications in squamous cell cancer <strong>of</strong> the<br />

lung are frequent (16%) and associated with smoking history. Screening for<br />

FGFR1 might pave the way for the application <strong>of</strong> new FGFR1 directed<br />

targeted drugs in squamous cell lung cancer.<br />

Cancer Prevention/Epidemiology<br />

93s<br />

1531 Poster Discussion Session (Board #20), Sun, 8:00 AM-12:00 PM and<br />

11:30 AM-12:30 PM<br />

Never-smoking women with lung cancer from the Spanish WORLD07<br />

database. Presenting Author: Dolores Isla, Hospital Lozano Blesa, Zaragoza,<br />

Spain<br />

Background: Gender differences in lung cancer (LC) have been reported,<br />

but with many unresolved issues yet. Tobacco causes the majority <strong>of</strong><br />

women lung cancer (WLC), although the rate <strong>of</strong> never-smoking WLC is<br />

higher than in men. Several factors may play etiologic roles, and an<br />

in-depth understanding is needed. Methods: WORLD07 is a Spanish<br />

prospective, multicenter, epidemiologic female-specific LC database sponsored<br />

by ICAPEM, a pr<strong>of</strong>essional association committed with WLC research.<br />

In order to improve the knowledge on never-smoking WLC,<br />

information has been extracted from WORLD07 database. Results: From<br />

October/2007 to October/2011, 1371 newly diagnosed WLC were included<br />

in an e-database from 32 centers, 539 (39.3%) never-smoking.<br />

Patient (p) characteristics: median age 71.1 years(y); median age <strong>of</strong><br />

menarche 13y.; motherhood 91.2% (median 2.3 children, median age at<br />

first child 26.4y); oral contraceptive use 11.9%; postmenopausal 88.9%<br />

(median age <strong>of</strong> menopause 49y); HRT 5.2%; second-hand smokers 40%<br />

(work-exposure 17.1%, home-exposure 88.8%); obesity 16.3%; familiar<br />

history <strong>of</strong> cancer 39.9% (LC 29.8%); previous history <strong>of</strong> cancer 13%<br />

(breast/lung/cervix: 41.4/5.7/2.9%); current LC histology(%): adenocarcinoma/SqCC/LCC/SCLC:<br />

83.4/6.2/5.5/3.9; EGFR mut� (268 p analyzed):<br />

55.5% (exon 19/20/21(%): 61.1/7.4/36.9); TNM NSCLC I/II/III/IV(%):<br />

14/3.3/19.8/60.3. Treatment: EGFR-TKI in p EGFR mut�, stage IV(1st-/ 2nd-line)(%): 51.7/15.4; stage IV NSCLC (1st-line/2nd-line): platinumbased<br />

CT 42.5%, EGFR-TKI 33.5%, combinations with bevacizumab<br />

2.9% / EGFR-TKI 15.8%. Overall survival: median 27 months(m), 1/2y(%)<br />

74.8/55.2; stage IV NSCLC: median 20.5m, 1/2-y(%) 67/46;<br />

EGFR-mut� p: median 27.3m, 1/2-y(%) 75/54.3. Conclusions: According<br />

to our e-database, WLC showed high rates <strong>of</strong> never-smokers (39.3%), and<br />

<strong>of</strong> relatives diagnosed with malignant tumours (39.9%, �1/3 LC). Adenocarcinoma<br />

was the most frequent histology (76.1%), and more than half <strong>of</strong><br />

the cases analyzed harboured EGFR mutations. Although 40% were<br />

second-hand smokers, further investigations are warranted. Survival outcomes<br />

remain satisfactory, as expected from this selected subgroup <strong>of</strong> p.<br />

Additional epidemiologic and treatment data will be presented.<br />

1534 Poster Discussion Session (Board #23), Sun, 8:00 AM-12:00 PM and<br />

11:30 AM-12:30 PM<br />

Molecular epidemiological prospective study <strong>of</strong> EGFR mutations from<br />

Asian patients (pts) with advanced lung adenocarcinoma (PIONEER).<br />

Presenting Author: Pan-Chyr Yang, National Taiwan University Hospital,<br />

College <strong>of</strong> Medicine, Taipei, Taiwan<br />

Background: The epidemiological, multicenter prospective study<br />

(NCT01185314; PIONEER) assessed EGFR mutation (M) rates in pts from<br />

Asia with newly diagnosed advanced lung adenocarcinoma (ADC). Influence<br />

<strong>of</strong> demographic and clinical factors on EGFR M rates was investigated.<br />

Methods: Pts were aged �20 years, with treatment naïve stage<br />

IIIB/IV lung ADC. Tumor sample (biopsy, surgical specimen, cytology)<br />

EGFR M status (primary endpoint; positive [M�], negative [M-], undetermined<br />

[MU]) was determined using Scorpion ARMS (Therascreen EGFR<br />

RGQ kit). EGFR M frequency was calculated and compared between<br />

demographic/clinical factor subgroups (chi-square/Fisher’s exact test).<br />

Factors with p�0.05 in the univariate analysis were further analyzed by<br />

multivariate logistic regression at 1% significance level to take the large<br />

dataset into consideration. Results: Of 1482 pts from 7 Asian countries,<br />

43.4% were female, mean age was 60 years (range 17-94), and 52.6%<br />

were never-smokers. EGFR M status was evaluated in 1450 patients (32<br />

[2.2%] were MU): 746 (51.4%) were M�, 704 (48.6%) were M-. Country,<br />

gender, ethnicity, smoking status, pack years, metastasis, (all p�0.001)<br />

and disease stage (p�0.009) correlated significantly with EGFR M status.<br />

EGFR M� rate by country: Vietnam 64.2% (77/120), Taiwan 62.1%<br />

(108/174), Thailand 53.8% (63/117), Philippines 52.3% (34/65), China<br />

50.2% (372/741), Hong Kong 47.2% (76/161), India 22.2% (16/72).<br />

EGFR M� rates were 61.1% in females, 44.0% in males, 60.7% in never<br />

smokers, and 31.4% in heavy smokers (�50 pack years). EGFR M� rates<br />

were 37.5% in male regular smokers (113/301), 34.8% in female regular<br />

smokers (8/23), 56.5% in male never smokers (104/184) and 62.0% in<br />

female never smokers (358/577). Ethnic group (p�0.001) and pack years<br />

(p�0.001) were identified as important factors by logistic regression;<br />

gender was not significant when adjusted for smoking status. Conclusions:<br />

The overall EGFR M� rate in unselected ADC was 51.4%. Ethnicity and<br />

pack years were found to have a statistically significant association with<br />

EGFR M rates. There was no association between gender and EGFR M rates<br />

when adjusted for smoking status.<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!